ArticlePloS one2024

Comparison of safety profiles for dapagliflozin based on EMA and FDA safety issues: Challenges and future of post-marketing surveillance in Korea.

Suvin Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.